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Intrinsic immunity relies on specific recognition of viral epitopes to mount a cell-autonomous defense against viral
infections. Viral recognition determinants in intrinsic immunity genes are expected to evolve rapidly as host genes
adapt to changing viruses, resulting in a signature of adaptive evolution. Zinc-finger antiviral protein (ZAP) from rats
was discovered to be an intrinsic immunity gene that can restrict murine leukemia virus, and certain alphaviruses and
filoviruses. Here, we used an approach combining molecular evolution and cellular infectivity assays to address
whether ZAP also acts as a restriction factor in primates, and to pinpoint which protein domains may directly interact
with the virus. We find that ZAP has evolved under positive selection throughout primate evolution. Recurrent positive
selection is only found in the poly(ADP-ribose) polymerase (PARP)–like domain present in a longer human ZAP isoform.
This PARP-like domain was not present in the previously identified and tested rat ZAP gene. Using infectivity assays,
we found that the longer isoform of ZAP that contains the PARP-like domain is a stronger suppressor of murine
leukemia virus expression and Semliki forest virus infection. Our study thus finds that human ZAP encodes a potent
antiviral activity against alphaviruses. The striking congruence between our evolutionary predictions and cellular
infectivity assays strongly validates such a combined approach to study intrinsic immunity genes.
Citation: Kerns JA, Emerman M, Malik HS (2008) Positive selection and increased antiviral activity associated with the PARP-containing isoform of human zinc-finger antiviral
protein. PLoS Genet 4(1): e21. doi:10.1371/journal.pgen.0040021
Introduction
Recent discoveries have highlighted the role of intrinsic
immunity genes in primate host defense against viral
infections [1–3]. These genes are predicted to be locked in
ancient, ongoing genetic conﬂicts with an ever-changing
repertoire of viral infections [4–6]. Consistent with this
prediction, the primate genes that encode for intrinsic
immunity have been found to be evolving under positive
selection, wherein they accumulate an excess number of non-
synonymous substitutions (protein-altering, dN) compared to
synonymous substitutions (no effect on protein, dS). This
kind of selective pressure is seen in cases where innovation in
protein sequence can result in a selective advantage and
rapid ﬁxation, as is the case for a host immunity gene where a
single mutation might improve its ability to recognize and
destroy a pathogen. In fact, genome-wide scans for positively
selected genes in primates reveal that adaptively evolving
genes fall primarily into three functional categories: immune
defense, chemosensory perception, and reproduction, with
the majority of these genes being involved in immunity [7].
Four known groups of intrinsic immunity genes have been
preserved over a broad taxonomic range; APOBEC3G and
other APOBEC3 genes as well as TRIM5 are conserved across
many mammalian orders [8,9], while Fv1 is conserved in many
Mus species [10]. All three of these groups of these intrinsic
immunity genes have been shown to evolve under positive
selection [4–6,10]. A signature of positive selection has not
only provided information about the antiviral activity and
age of these ‘‘restriction’’ genes, but has also helped to
identify protein domains at the direct interface of the host–
virus interaction [4].
The fourth intrinsic immunity gene that is present over a
broad taxonomic range is the zinc-ﬁnger antiviral protein (ZAP).
ZAP from rat cells (referred to as rZAP) was identiﬁed due to
its ability to signiﬁcantly impair the replication of the mouse
retrovirus, murine leukemia virus (MLV), through a mecha-
nism that involves binding and degrading viral RNAs in the
cytoplasm [11]. Viral RNA recognition by rZAP is mediated
by the 4 CCCH zinc ﬁnger motifs, which have been shown to
directly bind viral RNA with high speciﬁcity [12]. ZAP-
dependent recruitment of an RNA processing exosome in the
cytoplasm then leads to viral RNA degradation [13]. Sub-
sequent studies have found that rZAP can inhibit both
alphaviruses [14,15] and ﬁloviruses [16] by inhibiting the
translation of incoming viral RNA. We undertook a combined
approach using an evolutionary analysis of ZAP orthologs in
primates as well as functional tests of ZAP isoforms from
humans.
The human ortholog of the ZAP gene encodes 2 protein
isoforms that result from alternative splicing of a carboxy-
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This PARP-like domain is present in ZAP(L) and absent in
ZAP(S). Two shorter rat ZAP isoforms have previously been
described, one corresponding to human ZAP(S) and the other
to just the ﬁrst 254 amino acids of the N-terminus (rat NZAP),
and neither contain the PARP-like domain[11]. Our evolu-
tionary analysis of ZAP revealed strong evidence of positive
selection throughout primate evolution. By examining the
pattern of evolutionary change in this gene, we found,
surprisingly, no evidence for positive selection in ZAP’s
CCCH RNA-binding domain. This implies that rapid alter-
ations of viral mRNA binding have not driven ZAP evolution.
Instead, the signature of positive selection in primate ZAP is
conﬁned to the PARP-like domain, implicating this domain as
an uncharacterized and evolutionarily important interface
for ZAP–virus interactions. Using infectivity assays, we show
that human ZAP is capable of restricting expression of the
retrovirus, MLV, as well as infection by the alphavirus, Semliki
Forest virus (SFV), in human cells. Moreover, we show that the
presence of the PARP-like domain in the longer human ZAP
isoform signiﬁcantly enhances this restrictive capability
against both viruses, making this the ﬁrst demonstration of
a PARP-like domain being implicated in an immunity role.
Our results demonstrate that a combination of evolutionary
and virological analyses can identify and validate speciﬁc
protein domains involved in host–pathogen interactions,
thereby uncovering previously unknown antiviral activity.
Results
Two Predominant ZAP Isoforms
The human ZAP gene comprises 13 exons spanning
approximately 60 kb (Figure 1A). The two reported alter-
natively spliced isoforms of human ZAP code for proteins
that either lack or contain a carboxy-terminal PARP-like
domain (Refseq NM_020119.3 and NM_024625.3). We refer
to the short and long isoforms as ZAP(S) and ZAP(L),
respectively (Figure 1A). The ZAP(L) isoform encodes a
protein with an N-terminal CCCH domain (four CCCH
motifs), a TPH, or TiPARP Homology domain (conserved
among ZAP paralogs and containing a ﬁfth zinc ﬁnger motif),
a WWE domain (predicted to mediate speciﬁc protein–
protein interactions in ubiquitin and ADP–ribose conjuga-
tion proteins [17]) and a C-terminal PARP-like domain. The
antiviral activity of rZAP was ﬁrst discovered using a
truncated rat ZAP protein (rat NZAP), which consisted only
of the 4 CCCH motifs that mediate RNA binding [11] (Figure
1A). Subsequent analyses revealed that a longer rZAP protein
also has antiviral ability. However, even this rat ZAP,
presumed at the time to be ‘‘full length,’’ corresponds to
the human ZAP(S) isoform and does not include the C-
terminal PARP domain.
To gauge the tissue-speciﬁcity of the two human isoforms
relative to each other, we used RT-PCR from a human tissue
cDNA panel and primers speciﬁc to the ZAP(S) and ZAP(L)
isoforms (Figure 1B). We found that ZAP(S) is expressed has a
broader expression pattern compared to the ZAP(L) isoform.
However, the ZAP(L) isoform is expressed in tissues where it
may mediate an intrinsic immunity function, including
germline tissues and peripheral blood lymphocytes (PBLs).
Indeed, the tissue range of ZAP(L) is comparable to some of
the APOBEC3 genes that we have analyzed previously using
the same cDNA panel [6].
Next, we wanted to address whether ZAP(L) is limited to the
primate lineage. The Refseq entries for both mouse and rat
ZAP proteins only refer to a protein equivalent of human
ZAP(S). On examining the genomic sequence context for both
rat and mouse ZAP genes, we found that they both have a
downstream set of exons that could encode a putative PARP
domain that would be orthologous to that from primate
ZAP(L). In order to determine whether these exons are spliced
onto the remainder of the ZAP gene, we performed RT-PCR
using RNA from rat liver and primers designed to the WWE
domain (shared between both ZAP(S) and ZAP(L) isoforms)
and the PARP domain. Indeed, we found that the rat ZAP
gene can encode a ZAP(L) isoform that includes a C-terminal
PARP domain (Figure 1A). The reason this isoform appears to
have been missed until now is because no ESTs corresponding
to this PARP domain have been reported, suggesting that
ZAP(L) may be more weakly expressed than ZAP(S) in rodents,
as is the case in humans (Figure 1B).
In terms of overall architecture and paralogous genes, ZAP
is most closely related to 3 other PARP-containing genes:
PARP11, PARP12, and TiPARP [18] as well as ZRP2, which only
consists of a CCCH domain (Figure S1). Putative orthologs for
all ﬁve genes can be found in genome sequences from a
variety of mammals, as well as chicken and ﬁsh, suggesting that
this gene family is ancient [19] and that the PARP-containing
ZAP isoform dates back to the origin of vertebrates.
Positive Selection of Primate ZAP
To investigate whether the ZAP gene has evolved under
positive selection during primate evolution, we sequenced the
ZAP(L) coding sequence (2.7 kb) via RT-PCR from 13 primates
representing 33 million years of evolution. Our analysis
included 6 hominoids, 3 Old World monkeys (OWM), and 4
New World monkeys (NWM). The phylogeny constructed
from the primate ZAP sequences was congruent with the
generally accepted primate phylogeny conﬁrming that the
sequences are orthologous (Figure 2A). Using the free-ratio
model in the PAML suite of programs [20], which allows an
independent assignment of dN/dS ratios to each evolutionary
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Author Summary
Host–virus interactions are a classic example of genetic conflict in
which both entities try to gain an evolutionary advantage over the
other. This ‘‘back-and-forth’’ evolution is predicted to result in rapid
changes of both host and viral proteins, which results in an
evolutionary signature of positive selection, especially at the direct
interaction interface. Recent studies have demonstrated that host
proteins can target intracellular stages of the viral life cycle to
potently inhibit viruses. Collectively, these host proteins are referred
to as ‘‘intrinsic immunity’’ proteins. One such protein, zinc-finger
antiviral protein (ZAP), was previously described from rats and
shown to inhibit retroviruses and alphaviruses. We queried the
primate orthologs of ZAP to ascertain both whether they have
evolved under positive selection, and whether they have antiviral
activity. We found that the signature of positive selection was
restricted to a poly(ADP-ribose) polymerase–like domain in a longer
isoform of primate ZAP. The longer human ZAP isoform has
increased antiviral activity against both retroviruses and alphavi-
ruses. Thus, positive selection correctly predicted the more potent
antiviral isoform of this protein.branch, we found that several branches of the phylogeny show
dN/dS . 1 (bold numbers in Figure 2A). Furthermore, when
we compared the likelihood of ZAP evolution under codon
models that prohibit (Nsites models M1, M7, or M8a) or
permit positive selection (M2 and M8), we found that models
permitting positive selection ﬁt ZAP evolution signiﬁcantly
better than those that disallow it (p , 0.0003, Table 1). This
indicates that ZAP has evolved under positive selection
during primate evolution, suggesting it has a long history of
actively participating in host–pathogen interactions.
To determine which domains were responsible for the
signature of positive selection in ZAP, we performed three
separate PAML analyses using the N-terminal CCCH domain
(amino acids [aa] 1–240), the central domain containing the
TPH and WWE motifs (aa 241–700), or the C-terminal PARP
domain (aa 701–902). Signiﬁcantly, our PAML analyses did
not reveal any evidence for positive selection acting on the N-
terminal CCCH domain. Indeed, we found a high degree of
conservation of the CCCH domain throughout mammalian
evolution (Figure S1), arguing that rapid alteration of viral
RNA-binding has not had a signiﬁcant impact on ZAP
evolution. Sliding window dN/dS analyses based on different
pairwise alignments of primate ZAP genes suggests that
positive selection may have episodically acted on the central
domain containing the TPH and WWE motifs (aa 241–700;
Figure S2). However, since no codons show a recurrent
signature of positive selection, these domains are not high-
lighted by the PAML analyses (Table 1).
Rather, we found a robust signature for positive selection
in the PARP-like domain (aa 701–902; Table 1). We found
that a model of episodic positive selection (Free Ratio) was
signiﬁcantly more likely than a model of constant positive
selection (Model 0, one ﬁxed dN/dS; p ¼ .01, df ¼ 21),
suggesting that ZAP has been engaged in episodic conﬂicts
with exogenous infectious agents. Three codons were
identiﬁed as having evolved under recurrent positive
selection in the PARP domain, using both PAML and REL
analyses (Table 1) [20,21]. Surprisingly, the three residues for
which we obtained high conﬁdence of positive selection
(Figure 2B) are found in close proximity to residues that are
thought to mediate the contact residues for NADþ binding
(cd01439.2 from the CDD database [22] largely modeled from
the crystal structure of the chicken PARP-1 catalytic domain
[23,24]). This is highly unexpected because it would seem that
these residues should be highly constrained as part of PARP
or PARP-like function, for which NADþbinding is obligatory.
It is possible that these residues could be rapidly evolving
because of ZAP(L) interactions with viral proteins that may
Figure 1. ZAP(S) and ZAP(L) Isoforms in Mammals
(A) Schematic of the genomic structure of human ZAP(L) and the protein structure with previously defined domains (CCCH fingers, TPH, WWE, and
PARP-like). The asterisk indicates the stop codon for an alternative transcript that has been reportedly isolated from multiple cDNA libraries. An
additional transcript with an alternatively spliced exon (366 bp) inserted after exon 4 was also identified in several primates (not shown) but not in
human, so our evolutionary analysis was limited to the ZAP(L) isoform shown. The rat NZAP (254 aa) protein structure is shown for comparison. A longer
ZAP(L) isoform was also detected by RT-PCR from rat liver RNA using a forward primer in the WWE domain (exon 7) and a reverse primer in the PARP
domain (exon 13) (see arrows). The resulting product was directly sequenced and corresponded to exons 7–13 of rat ZAP (gel inset).
(B) Human ZAP isoforms are expressed in a wide range of tissues, including germline tissues and peripheral blood lymphocytes (PBLs). Results from PCR
amplification from a human multiple tissue cDNA panel with primers specific to the human ZAP(S) and (L) isoforms (top and bottom panels,
respectively). Lanes are labeled according to the template tissue (M, DNA standard marker; blank, no template).
doi:10.1371/journal.pgen.0040021.g001
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Thus, contrary to expectation, the only signature of
recurrent positive selection we found in primate ZAP
evolution is limited to a domain that is missing from the
rZAP gene, which is the only version that has been previously
tested in any antiviral assays. Since protein innovation has
been primarily favored exclusively in the PARP domain, this
would predict that ZAP(L) is the more evolutionarily relevant
antiviral isoform. This prediction can be directly evaluated
by testing whether the region under the most intense positive
selection, the PARP-like domain, enhances the antiviral
activity of ZAP.
Human ZAP(L) Is a More Potent Viral Inhibitor than ZAP(S)
The original identiﬁcation of rat NZAP was based on its
ability to inhibit MLV infection and MLV long terminal
Figure 2. Positive Selection of ZAP(L) in Primates
(A) Ancient signature of positive selection in primate ZAP. A sequence alignment of ZAP(L) from four New World monkeys, three Old World monkeys,
and six hominoids was analyzed using the free-ratio model from PAML, which allows dN/dS to vary along each branch. The corresponding dN/dS values
are shown for each branch, and bold numbers indicate those branches with dN/dS . 1. In the case of no observed synonymous changes (inf), a dN/dS
ratio could not be calculated.
(B) An alignment of a segment of the PARP domains from these primate species is shown. Identical and similar residues are indicated with asterisks (*)
and colons (:), respectively. The 3 residues identified with high confidence as evolving under positive selection are indicated with exclamation marks
and lie in close proximity to the NADþ binding contact residues (indicated by yellow boxes).
doi:10.1371/journal.pgen.0040021.g002
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ZAP Evolution and Function in Primatesrepeat (LTR)–based expression. We created HA-tagged
human ZAP(L) and ZAP(S) expression constructs in parallel
with the previously described rat NZAP clone [11] and then
tested their restrictive capabilities by co-transfecting increas-
ing amounts of ZAP plasmid with a MLV-based vector, in
which the ﬁreﬂy luciferase reporter gene is inserted between
the 59 and 39 LTRs of MLV. A similar MLV-based luciferase
reporter construct was previously used to show that the 39
LTR sequence of MLV is the target of the CCCH domain of
rat NZAP [12]. In repeated luciferase assays (n ¼ 6), we found
that all ZAP expression plasmids signiﬁcantly suppressed
MLV LTR-driven luciferase expression (Figure 3A). Our
experiments also show that ZAP(L) is a 2- to 3-fold stronger
suppressor of MLV than ZAP(S) at the highest tested levels of
ZAP (200 ng; Figure 3A–3B). In addition, Western analysis of
lysates from the comparable transfections reveals that the
ZAP(S) expression level is signiﬁcantly higher than ZAP(L)
(Figure 3C), despite equal amounts of transfected plasmid.
This suggests a secondary control of ZAP(L) expression, which
we have not explored further. However, these results do
imply that the 2- to 3-fold higher inhibition of MLV
expression seen with ZAP(L) is likely to be a signiﬁcant
underestimate. As a control, we also tested whether the ZAP
isoforms were effective at inhibiting a similar construct that
utilized the LTR from HIV to drive luciferase gene
expression. We found that human ZAP(L), ZAP(S) and rat
NZAP had no effect on HIV LTR-driven luciferase (Figure
3D), suggesting a strong speciﬁcity for retroviral inhibition, as
was previously reported for rat NZAP [11]. These results
demonstrate human ZAP has potent antiviral function, and
that ZAP(L) is a more effective inhibitor than ZAP(S).
Previous results have also demonstrated that rZAP can
inhibit alphaviruses [14]. Therefore, we tested whether the
two human ZAP isoforms were also capable of restricting an
alphavirus, SFV, using a previously described DNA-based
recombinant SFV vector system that expresses the b-gal gene
[25]. We performed single-round infectivity assays in HeLa
cells lines stably-expressing HA-tagged human ZAP(L),
human ZAP(S), or rat NZAP. The expression level of ZAP(L)
was about equal to that of ZAP(S), while rat NZAP appeared
to be more highly expressed in our cell lines (Figure 4A).
While ZAP(L), ZAP(S) and rat NZAP all demonstrate antiviral
activity against SFV infection, ZAP(L) was signiﬁcantly more
potent than the other isoforms, with almost 10-fold inhibition
of SFV compared to only 2-fold inhibition by either ZAP(S) or
rat NZAP (Figure 4B). To assess whether the antiviral activity
of human ZAP is a general antiviral effect (and to rule out the
possibility that our observations are due simply to greater cell
death in ZAP(L)-expressing cells), we performed single-round
infectivity assays with HIV expressing luciferase in HeLa cells
stably expressing the ZAP isoforms. We found that none of
the isoforms of ZAP were capable of signiﬁcantly inhibiting
HIV infection, demonstrating that the antiviral activity of
ZAP is virus-speciﬁc (Figure 4C). Intriguingly, the expression
of human ZAP isoforms in baby hamster kidney (BHK) cells
did not confer resistance to SFV (unpublished data), suggest-
ing that the rapid evolution of ZAP has likely resulted in
species-speciﬁc restriction and that ZAP restriction of
alphaviruses is at least partially dependent on the context
of other host proteins.
Discussion
Our evolutionary analyses of primate ZAP(L) reveals that
the C-terminal PARP-like domain encoded only by the ZAP(L)
isoform is in fact the only domain that is under recurrent
positive selection. Based on this insight from our evolu-
tionary analysis, we tested the abilities of both human ZAP(L)
and ZAP(S) isoforms to inhibit SFV and HIV infection in
human cells. Our results clearly demonstrate that human ZAP
can inhibit SFV, but not HIV, and that the presence of the
PARP domain signiﬁcantly enhances the ability of ZAP to
suppress SFV infection. While previous work also implicated
the rat ZAP as an inhibitor of the murine retrovirus, MLV, in
rodent cells [11], we do not observe such an effect against
MLV infection (unpublished data) at the level of ZAP
expressed in our stable human cell lines, even though we do
see an effect on SFV infection in the same cell lines.
Therefore, we believe that the viral antagonist(s) that drove
ZAP evolution in primates was likely a member of the
Togaviridae family [14,15] rather than the Retroviridae family.
The rZAP CCCH domain can be very speciﬁc in its RNA-
binding and antiviral activity [12]. Our experiments on MLV
and HIV (Figure 3) suggest that the RNA-binding speciﬁcities
of rodent and primate ZAP are not signiﬁcantly different.
Our analyses cannot rule out the possibility that some subtle
alteration of RNA-binding may have occurred during the
course of mammalian evolution. However, the absence of
positive selection in the CCCH domain unambiguously rules
out an evolutionary conﬂict scenario in which the restrictive
ability of ZAP was shaped by repeated episodes of selection
for dramatic alterations in RNA-binding activity.
It is not yet clear what role a PARP-like domain could play
in ZAP function. PARP function has been primarily charac-
terized in the nucleus where it is believed that the addition of
ADP-ribose moieties to chromatin proteins results in their
looser association with DNA, thereby allowing greater access
to transcription and DNA repair machineries [19,26–28]. A
similar mechanism of protein modiﬁcation by ZAP’s PARP
domain could be imagined to disrupt binding by viral RNA-
binding proteins (Figure S4). However, the ZAP PARP-like
Table 1. Likelihood Ratio Test Statistics for Models of Variable
Selective Pressure Among Sites
ZAP Region Analyzed 2lnk df p-Value
Full gene (aa 1–902) 15.0 2 ,0.003
N-terminal CCCH domain (aa 1–240) 5.1 2 .0.05 (N.S.)
Central TPH/WWE domain (aa 241–700) 3.5 2 .0.1 (N.S)
C-terminal PARP domain (aa 701–902) 16.5 2 ,0.001
We calculated log-likelihood ratios between the NSsites models, model 7 (M7, fit to a beta
distribution, dN/dS . 1 disallowed), and model 8 (M8, similar to model 7, but dN/dS . 1
allowed) under the F61 model of codon substitutions. The M8 model provided a
significantly better fit than M7 for the whole gene and for the PARP-containing domain 3
(aa 701–992), but not for domain 1 (CCCH domain) or domain 2. Using both the Nssites
models and REL analysis, we also identified specific amino acid residues as having evolved
under positive selection (numbered according to human ZAP(L)): L730 (.79, .82, 7461),
K770 (.63, .66, 5632), S776 (.56, .51, 286), Y793 (.99, .99, 5.1 3 10
6), S799 (.80, .82, 4201),
S804 (.97, .98, 2.3310
5), F805 (.99, .99, 3.3310
7), I855 (.62, .65, 3585), and Q863 (.87, .88,
7831). The numbers in parentheses correspond to the individual probabilities, NEB, BEB
(from NSsites) [21], and Bayes factor (from REL) [21], respectively. Codons with a posterior
probability .95% are in bold.
k, likelihood; df, degrees of freedom; N.S., not significant.
doi:10.1371/journal.pgen.0040021.t001
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glutamic acid (position 988 in PARP-1) and therefore may not
be catalytically active as a canonical PARP [29], although its
NADþ binding site is conserved.
While the mechanism by which the PARP-like domain
mediates its antiviral effect is unknown, we can still address
why the PARP-like domain has been evolving under positive
selection. Using the model for antagonistic host–pathogen
interactions, there are several possible scenarios for the
adaptive evolution of the PARP-like domain in ZAP: either
the PARP domain evolves towards recognizing the virus, or it
evolves away from being recognized by the virus. In the ﬁrst
scenario, the PARP-like domain may increase ZAP’s afﬁnity
for viral mRNA binding proteins (analogous to APOBEC3G
associating with nucleocapsid [30]), in which case the PARP-
like domain is under selective pressure to increase binding to
viral proteins. The alternate possibility is that viruses may
encode speciﬁc antagonists to bind ZAP’s PARP domain and
sequester or degrade ZAP (analogous to Vif degradation of
APOBEC3G [31]), in which case the selective pressure on ZAP
PARP would be to decrease binding with viral antagonists. We
favor the latter possibility because the residues that show a
recurrent signature of positive selection also fall proximal to
the NADþbinding sites, which may be essential for any PARP-
like function. Given the recent re-emergence of alphavirus
epidemics in Africa and Asia and the reports of alphavirus
disease in Europe [32,33], our discovery that human ZAP
encodes a potent anti-alphaviral activity that depends on the
PARP domain may guide future strategies for therapeutic
drug design to treat alphavirus-related disease.
Materials and Methods
RT-PCR and sequencing. Human, chimp, and rhesus ZAP
sequences were obtained from the respective genome projects. We
Figure 3. ZAP Viral Inhibition Is Specific to MLV but Not HIV, and the PARP Domain Enhances the Viral Restriction
Co-transfections of ZAP isoforms with the LlucSN (MLV) or pwtLTR-luc1 (HIV) promoter constructs were used to assess the ability of the ZAP isoforms to
restrict HIV- and MLV-driven luciferase.
(A) ZAP inhibits MLV in cells transfected with equal amounts of the ZAP expression constructs. Equal amounts of each ZAP expression construct were
co-transfected with LlucSN (MLV). All transfections were equalized for DNA amount with the addition of pcDNA. Lysates from transfected cells were
collected after 24 h, and luciferase activity was measured.
(B) Effect of increasing amounts of transfected human ZAP(L) or ZAP(S) DNA on MLV-LTR driven luciferase expression. Lysates from transfected cells
were harvested at 48 h, and luciferase activity was measured. Results are shown as percent luciferase expression of the control transfection (no ZAP).
The results from one representative experiment are shown, with error bars reflecting the variation between triplicate infections within one experiment.
(C) Equivalent amounts of lysates from 293T cells transiently co-transfected with different amounts of ZAP expression constructs and the MLV LTR-luciferase
construct were analyzed by Western blot analysis to determine the relative amount of protein. Samples were harvested 48 hours after transfection. Sizes of
HA-tagged ZAP(L), ZAP(S), and rat NZAP are ;115 kDa, ;80 kDa, and ;30 kDa, respectively. Actin was the loading control. To determine the relative
amounts of ZAP(L) and ZAP(S), Western blot analysis was performed on a dilution series of lysates from 293T cells transfected with the ZAP constructs.
(D) For ZAP and HIV co-transfections, pwtLTR-luc1 (HIV) was co-transfected with either no ZAP, ZAP(L), ZAP(S), or rat NZAP (a CMV-Tat construct was
also transfected to improve expression levels of HIV). Transfections and luciferase assays were performed as in the MLV experiment.
doi:10.1371/journal.pgen.0040021.g003
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PCR using RNA isolated from individual cell lines (obtained from
Coriell and E. Eichler [gibbon]). RT-PCR was done in two overlapping
fragments using the Invitrogen One-Step RT-PCR with Platinum Taq
kit (Invitrogen). To amplify the 59 half of the gene, we used the
following primers to generate a 1.4 kb fragment: Forward-59
ATGGCGGACCCGGAGGTG, Reverse-59 CTCGGGAAGCAGGTC
CAGCATCC. The 39 half of the gene was ampliﬁed as a 1.4 kb
fragment with the following primers: Forward-59 AATGCTGATG
GAGTGGCCACAG, Reverse-59 GACAACTAACTAATCACG
CAGGCTTTGTC. To demonstrate the existence of a PARP-contain-
ing rat ZAP (L), the following primers were used to generate a
fragment spanning exons 7–13 of ZAP: Forward-59 TCTGACTCC
TACCCCATCCGA, Reverse-59 GCAACCTTTCTCTTTCTCTGATTC
CAC. All sequencing was done using ABI BigDye version 3.0.
Nucleotide sequence accession numbers. Sequences obtained in
this study were deposited in Genbank and assigned accession
numbers EF494425–EF494434.
Expression panels. To detect ZAP expression in different human
tissues, we used human cDNA panels in which 5 ng of ﬁrst-strand
cDNA from various tissues were preloaded (Primgen) and performed
PCR using primers speciﬁc to either the ZAP(S) or ZAP(L) isoform.
Evolutionary analyses. We used Clustal_X [34] to generate a
multiple alignment for ZAP from all primate species sequenced.
Maximum likelihood analysis was performed with codeml in the PAML
3.14.1 software package [35]. To detect selection, multiple alignments
were ﬁtted to the NSsites models that disallow positive selection (M1,
M7, M8a) or to models that permit positive selection (M2, M8, M8b,
respectively) assuming the f61 model of codon frequencies. Simu-
lations were run with multiple starting values for dN/dS. Likelihood
ratio tests were performed to assess whether permitting codons to
evolve under positive selection gives a signiﬁcantly better ﬁt to the
data. To identify speciﬁc codons that are evolving under recurrent
positive selection, we used the NSsites model from codeml in the
PAML 3.14.1 software. To conﬁrm the sites identiﬁed by the codeml
approach, we also implemented the random effects method (REL)
from the online DataMonkey package, with a Bayes signiﬁcance factor
of 50 as the cutoff [21]. The REL approach differs from NSsites in that
it allows the synonymous substitution rate to vary among codons. Our
pairwise sliding window analyses were performed using the K-
estimator program [36], with a 300 bp window and a 50 bp slide.
Expression constructs. N-terminal hemagglutinin (HA)-tagged
human ZAP(L) and ZAP(S) were cloned by reverse transcription
(RT)-PCR from RNA isolated from 293T cells using the HA-speciﬁc 59
primer, 59-CAGGCGAATTCGCCACCATGTATCCATACGATGTTCC
AGATTACGCTGCGGACCCGGAGGTGTGC-39, and isoform-speciﬁc
39 primers as follows: HA-ZAP(L)-59 TTCAGGATATCCTAACTAAT
CACGCAGGC-39 and HA-ZAP(S)-59-TTCAGGATATCCTATCTCTT
CATCTGCTGCAC-39. The rat N-terminal HA-tagged NZAP was
cloned by RT-PCR from RNA isolated from Rat2 ﬁbroblasts using the
HA-speciﬁc 59 primer, 59-CAGGCGAATTCGCCACCATGTATCCA
TACGATGTTCCAGATTACGCTGCAGATCCCGGGGTA-39 and the
39 primer, 59-TTCAGGATATCTCAGTGAAGGAAGCGGTCTCT-39.
Each gene was transferred into the same mammalian expression
vector (pcDNA4; Invitrogen) which drives gene expression under the
cytomegalovirus IE94 (CMV) promoter. All constructs were con-
ﬁrmed by sequencing.
Cell culture. HeLa cells were cultured in Dulbecco’s modiﬁed Eagle
medium (DMEM) with 10% fetal bovine serum and were maintained
Figure 4. Human ZAP Restricts SFV Infection in Human Cells through the
PARP Domain
(A) Western analysis with anti-HA antibody shows expression of HA-
tagged human and rat ZAP isoforms in stably expressing HeLa cell lines.
Equal amounts of protein were loaded in each lane.
(B) SFV infection was strongly inhibited (7-fold) in HeLa cells stably
expressing ZAP(L), but only weakly restricted (2-fold) in HeLa cells stably
expressing ZAP(S) or rat NZAP. Cells were challenged with four 3-fold
serial dilutions of virus in quadruplicate and infectivity was determined
by measuring SFV-driven b-galactosidase activity as relative light units
using a luminescent substrate. The data are plotted as the means 6
standard deviation on a log scale.
(C) HIV infection was not attenuated in HeLA cells stably expressing the
ZAP isoforms. HeLa cells stably expressing the ZAP isoforms were
challenged by five 3-fold serial dilutions of virus, and infectivity was
determined by measuring HIV-driven luciferase activity (relative light units).
The data are plotted as the means 6 standard deviations on a log scale.
doi:10.1371/journal.pgen.0040021.g004
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constructs were individually transfected into HeLa cells using
Fugene6 Reagent (Roche) and stably expressing lines were selected
and maintained with Zeocin (0.1 mg/ml). The expression levels for
clonally derived lines were checked by Western analysis using an HA-
speciﬁc antibody (HA.11; Covance) and the highest expressing lines
were chosen for the infectivity assays.
Transient cotransfection, luciferase assay, and Western blot
analysis. Transient co-transfections were performed using the Mirius
TransIT-LTR Transfection reagent according to the manufacturer’s
recommendations. All cells were transfected with a total of 300 ng
DNA comprising 100 ng LlucSN plus empty pcDNA4 vector (No
ZAP), HA- ZAP expression plasmid (HA-hZAPL, HA-hZAPS, or HA-
rNZAP), as indicated, and the total DNA transfected was equalized
with empty pcDNA4 vector. After 48 h, the cells from triplicate
tranfections were lysed using 150 ll of Cell Culture Lysis reagent
(Promega). To quantify the luciferase activity, 20 ll of lysate was
analyzed with a Luciferase Assay kit (Promega) and luciferase activity
(light intensity) was measured with a luminometer.
For Western blot analysis, 293T cells were plated and transfected as
described above using different amounts of transfected HA-huZAP(L)
or HA-huZAP(S), with the total amount of transfected DNA equalized
using empty pCDNA4. After 48 h, the lysates from these cells were
harvested with NP-40-doc buffer (20 mM Tris [pH 8.0], 120 mM NaCl,
1 mM EDTA, 1% NP-40, 0.2% Na-deoxycholate, and protease
inhibitors [Roche complete cocktail tablets]), and incubated on ice
for 5 min and then frozen at 20 8C. Lysates were resuspended in SDS
loading buffer, boiled for 5 min, and then loaded and run on a 12%
NuPAGE Novex Bis-Tris Gel and transferred to nitrocellulose
membrane (Pierce). For HA-tagged ZAP protein detection, mem-
branes were probed with a HA-speciﬁc antibody (HA.11; Covance) at
a 1:2,000 dilution, followed by horseradish peroxidase (HRP)-
conjugated goat anti-mouse secondary antibody (Amersham Bio-
sciences) at a 1:3,000 dilution. For Actin protein detection, a rabbit
anti-Actin Ab (Sigma) was used at 1:10,000 dilution, followed by HRP-
conjugated donkey anti-rabbit secondary antibody (Amersham
Biosciences) at 1:3,000. Detection was performed with the ECL Plus
Reagent (Amersham Biosciences).
Virus stocks. SFV virus was made using the DNA-based Semliki
Forest Virus vectors (pSMARTlacZ and pSCAHelper), which were a
kind gift from Dr. Rod Bremner [25]. To make HIV virus stock we
used HIV-luc2Denv pseudotyped with VSV-G [37]. To make the virus
stocks, the constructs were transiently transfected into 293T cells
with FuGene6 Reagent (Roche). Virus released into the cell culture
supernatant by 48 h was harvested, clariﬁed by centrifugation, and
stored at  80 8C.
Single-cycle infectivity assays. SFV infections were performed as
previously described [25]. Brieﬂy, cells were plated in 96 well plates at
2 3 10
4 cells per well the day before infection. Virus was thawed and
treated with chymotrypsin to generate active virus and HeLa cell lines
(normal and stably expressing ZAP isoforms) were challenged with 3-
fold serial dilutions of active virus. After 24 h, the cells were lysed and
the b-galactosidase activity was measured using Galacton (Tropix) as a
substrate with 1-s measurements using a luminometer (Thermo
Fluoroskin Ascent, Thermo).
For the HIV infections, cells (normal or stably expressing ZAP
isoforms) were plated in 96-well plates at 2 3 10
4 cells per well and
after 24 h were challenged for 48 h with serial dilutions of HIV virus.
After 48 h, the cells were lysed using the Cell Culture Lysis reagent
(Promega). To quantify the luciferase activity, the lysate was analyzed
with a Luciferase Assay kit (Promega) and luciferase activity (light
intensity) was measured with a luminometer.
Supporting Information
Figure S1. Sliding Window dN/dS Analysis of Primate ZAP Genes
Sliding window (300 bp window, 50 bp slide) analyses of dN and dS
were performed, and 3 representative pairs of primate ZAP genes are
shown: (A) HOM-OWM (human versus patas monkey), (B) HOM-
NWM (human versus woolly monkey), and (C) OWM-NWM (rhesus
versus spider monkey). For each pairwise comparison, dN/dS (thick
line) and dS (thin line) are plotted against the length of the protein
with the schematic of the protein shown at the bottom. A dotted line
represents where dN/dS ¼ 1, consistent with the neutral expectation.
Found at doi:10.1371/journal.pgen.0040021.sg001 (270 KB PDF).
Figure S2. Multiple Sequence Alignment of Orthologous ZAP N-
Terminal Domains
An alignment of the ﬁrst 230 amino acids of ZAP, corresponding to
the CCCH zinc ﬁnger motifs, from 14 primates and six non-primate
mammals. Residues are highlighted in black or gray to indicate
complete conservation or high conservation, respectively. The
putative NLS is indicated between residues 69 and 76 and the four
CCCH ﬁngers are shown below the alignment.
Found at doi:10.1371/journal.pgen.0040021.sg002 (483 KB PDF).
Figure S3. ZAP Paralogs in Vertebrates
(A) There are at least four other proteins that share common
structural features with ZAP. ZRP2, PARP12, and ZAP are located on
7q34; TiPARP is on 3q25; and PARP11 is on 12p13. Only ZAP is
evolving under positive selection (red arrow).
(B) ZRP2 (NP_542391) is a predicted 300 amino acid protein that
contains the four CCCH type zinc ﬁngers found in ZAP. PARP12 and
ZAP share the CCCH ﬁngers, the TPH (including 1 CCCH ﬁnger),
WWE, and PARP-like domain. PARP11 and TiPARP lack the CCCH
domain but both contain the WWE and PARP-like domain.
Found at doi:10.1371/journal.pgen.0040021.sg003 (221 KB PDF).
Figure S4. A Hypothetical Model for How ZAP PARP-Like Activity
Might Enhance its Antiviral Function
(A) In the nucleus, PARP adds poly(ADP-ribose) (PAR) moeities to
chromatin proteins, thus loosening their association with DNA and
opening the chromatin structure, which allows greater access to
transcription and DNA repair machineries. This opening of the
chromatin structure is reversed by PARG, a glycohydrolase that
mediates the breakdown of PAR.
(B) Our model proposes that ZAP restricts viral replication by adding
PAR moieties to proteins associated with viral mRNAs in the
cytoplasm, thus weakening their interaction and exposing the mRNA
to exosomal degradation. Although PAR moeities are shown here,
even addition of Mono (ADP-ribose) could mediate the same effects.
It is presently unclear whether ZAP’s PARP domain possesses such
catalytic activity, since it is missing one of the critical catalytic
residues previously thought to be essential for PARP activity.
Found at doi:10.1371/journal.pgen.0040021.sg004 (708 KB PDF).
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